Kairos Pharma, Ltd. KAPA
AMEX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -20.68% | 14.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.15% | 19.43% | |||
| Operating Income | 16.15% | -19.43% | |||
| Income Before Tax | 16.08% | -21.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 16.08% | -21.17% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 16.08% | -21.17% | |||
| EBIT | 16.15% | -19.43% | |||
| EBITDA | 15.45% | -20.00% | |||
| EPS Basic | 17.69% | -20.25% | |||
| Normalized Basic EPS | 17.68% | -20.21% | |||
| EPS Diluted | 17.69% | -20.25% | |||
| Normalized Diluted EPS | 17.68% | -20.21% | |||
| Average Basic Shares Outstanding | 1.95% | 0.78% | |||
| Average Diluted Shares Outstanding | 1.95% | 0.78% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||